SCHEMBL9979912

SCHEMBL9979912

Cn1c2ccc(Br)cc2c2cc3c(cc21)c1cc(Br)ccc1n3C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.43
MCL1 Q07820 1/20 0.42
ACHE P22303 3/20 0.41
DNM1 Q05193 3/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
GPR3 P46089 1/20 0.41
SIGMAR1 Q99720 1/20 0.41
KDM4E B2RXH2 3/20 0.40
ALDH1A1 P00352 2/20 0.40
HPGD P15428 2/20 0.40
HSD17B10 Q99714 2/20 0.40
MEN1 O00255 1/20 0.40
HTT P42858 1/20 0.40
KMT2A Q03164 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
EGFR P00533 1/20 0.40
SRC P12931 1/20 0.40
CYP1A2 P05177 1/20 0.39
CCNB2 O95067 1/20 0.39
CDK1 P06493 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1921514 0.95 MAPT (0.46) MAPTMCL1ACHEDNM1SMN1; SMN2
SCHEMBL12418696 0.90 GPR3 (0.59) MAPTACHEGPR3KDM4EALDH1A1
SCHEMBL5014769 0.86 ACHE (0.41) MAPTMCL1ACHEDNM1SMN1; SMN2
SCHEMBL1923381 0.85 GPR3 (0.64) MAPTACHEGPR3KDM4EALDH1A1
SCHEMBL5532447 0.85 ACHE (0.47) MAPTMCL1ACHEDNM1SMN1; SMN2
SCHEMBL10871998 0.84 MAPT (0.45) MAPTMCL1ACHEDNM1SMN1; SMN2
SCHEMBL1929490 0.83 ACHE (0.51) MAPTMCL1ACHEDNM1SMN1; SMN2
SCHEMBL14479468 0.83 MAPK8 (0.48) MCL1ACHEALDH1A1MEN1KMT2A
SCHEMBL12418698 0.82 GPR3 (0.59) MAPTACHESMN1; SMN2GPR3KDM4E
SCHEMBL3281839 0.81 GPR3 (0.44) MAPTMCL1ACHESMN1; SMN2GPR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120157689-A1 SUBSTITUTED INDOLOCARBAZOLES XEROX CORPORATION (US) 2012-06-21 US disclosed
US-8110690-B2 Substituted indolocarbazoles XEROX CORPORATION (US) 2012-02-07 US disclosed
US-8003807-B2 organic thin film transistor with a semiconductor layer including the small molecule having didodecylindolo[3,2-b]carbazole groups XEROX CORPORATION (US) 2011-08-23 US disclosed
US-7868186-B2 Device containing polymer having indolocarbazole- repeat unit and divalent linkage XEROX CORPORATION (US) 2011-01-11 US disclosed
US-7829727-B2 Device containing compound having indolocarbazole moiety and divalent linkage XEROX CORPORATION (US) 2010-11-09 US disclosed
US-20100230670-A1 DEVICE CONTAINING COMPOUND HAVING INDOLOCARBAZOLE MOIETY AND DIVALENT LINKAGE XEROX CORPORATION (US) 2010-09-16 US disclosed
US-20090114909-A1 organic thin film transistor with a semiconductor layer including the polymer of 2,8-Bis(2-thienyl)-5,11-didodecylindolo[3,2-b]carbazole; organic photovoltaics XEROX CORPORATION (US) 2009-05-07 US disclosed
US-7528261-B2 Small molecule compound having indolocarbazole moiety and divalent linkage XEROX CORPORATION (US) 2009-05-05 US disclosed
US-20090036689-A1 SUBSTITUTED INDOLOCARBAZOLES XEROX CORPORATION (US) 2009-02-05 US disclosed
US-7456424-B2 Thin film transistors including indolocarbozoles XEROX CORPORATION (US) 2008-11-25 US disclosed
US-20080207917-A1 POLYMER HAVING INDOLOCARBAZOLE MOIETY AND DIVALENT LINKAGE XEROX CORPORATION (US) 2008-08-28 US disclosed
US-7402681-B2 Compound with indolocarbazole moieties and devices containing such compound XEROX CORPORATION (US) 2008-07-22 US disclosed
US-7396852-B2 Compound having indolocarbazole moiety and divalent linkage XEROX CORPORATION (US) 2008-07-08 US disclosed
US-20080103314-A1 SMALL MOLECULE COMPOUND HAVING INDOLOCARBAZOLE MOIETY AND DIVALENT LINKAGE XEROX CORPORATION (US) 2008-05-01 US disclosed
US-20070112167-A1 Device containing compound having indolocarbazole moiety and divalent linkage XEROX CORPORATION 2007-05-17 US disclosed
US-20070112172-A1 Compound having indolocarbazole moiety and divalent linkage XEROX CORPORATION 2007-05-17 US disclosed
US-7173140-B2 Process to form compound with indolocarbazole moieties XEROX CORPORATION (US) 2007-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090036689-A1 SUBSTITUTED INDOLOCARBAZOLES HTR3C, HTR3A, AANAT MAPT 196/4885MCL1 814/4885ACHE 1664/4885
US-20070112172-A1 Compound having indolocarbazole moiety and divalent linkage INMT, IDO2, GRIN2C MAPT 163/4885MCL1 964/4885ACHE 360/4885
US-20080103314-A1 SMALL MOLECULE COMPOUND HAVING INDOLOCARBAZOLE MOIETY AND DIVALENT LINKAGE SLC43A1, SLC7A5, KCNN2 MAPT 153/4885MCL1 2883/4885ACHE 1858/4885
US-20100230670-A1 DEVICE CONTAINING COMPOUND HAVING INDOLOCARBAZOLE MOIETY AND DIVALENT LINKAGE BRD4, BICRA, INMT MAPT 955/4885MCL1 2401/4885ACHE 152/4885
US-20080207917-A1 POLYMER HAVING INDOLOCARBAZOLE MOIETY AND DIVALENT LINKAGE SGTA, MTCL3, SMC3 MAPT 196/4885MCL1 1632/4885ACHE 2677/4885
US-20120157689-A1 SUBSTITUTED INDOLOCARBAZOLES HTR3C, HTR3A, AANAT MAPT 196/4885MCL1 814/4885ACHE 1664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.